THERESA ENGLUTT: Open Payments
NPI 1083355911 · DENISON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,206 in 199 payments from 28 companies in 2025. Trend: 2023 $1,185 · 2024 $2,494 · 2025 $6,206
Food & beverage: $4,039Consulting: $1,880Travel & lodging: $286
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 23 | $2,569 |
| GlaxoSmithKline, LLC. | 42 | $475 |
| AstraZeneca Pharmaceuticals LP | 15 | $422 |
| AOP Health US, LLC | 1 | $342 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $281 |
| Regeneron Healthcare Solutions, Inc. | 10 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $231 |
| Viatris Specialty LLC | 11 | $189 |
| Actelion Pharmaceuticals US, Inc. | 4 | $178 |
| Axsome Therapeutics, Inc. | 11 | $170 |
Products named: DUPIXENT, Rapiblyk, LUMRYZ, NUCALA, TRELEGY ELLIPTA, BREZTRI, GLASSIA, YUPELRI.
Industry payments across TX — which companies pay providers there.
